Close Menu

NEW YORK ─ Molecular diagnostics firm Progenity said on Monday that it plans to offer $25 million of shares of its common stock in a public offering and $75 million of convertible senior notes in a separate private offering.

The San Diego-based firm is granting the underwriters of the public offering a 30-day option to purchase up to an additional $3.75 million common shares at the public offering price. Piper Sandler and Wells Fargo Securities are joint book-running managers and BTIG is the lead manager for the offering of common stock.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.